Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

Published Date: 14 Jun 2024

Second-gen ALK inhibitor induces high response rate, associated with impressive survival

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

2.

For patients with prostate cancer, long-term follow-up helps identify treatment side effects.

3.

fresh E. Coli Outbreak: ECMO Redefining Death and Bringing Universal Blood One Step Nearer.

4.

NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.

5.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot